Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120430 | 0.80 | RAB9A (0.55) | RAB9AMEN1KMT2AALDH1A1GAA | |
| SCHEMBL1682777 | 0.80 | RAB9A (0.55) | RAB9AMEN1KMT2AALDH1A1GAA | |
| Acridine SCHEMBL27545385 | 0.79 | RAB9A (0.63) | RAB9AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL2425847 | 0.79 | HTT (0.58) | RAB9AMEN1KMT2AALDH1A1CASP6 | |
| SCHEMBL358410 | 0.79 | RAB9A (0.58) | RAB9AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28818163 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2AALDH1A1GAA | |
| SCHEMBL14661558 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2011679 | 0.79 | KMT2A (0.50) | RAB9AMEN1KMT2AALDH1A1IKBKB | |
| SCHEMBL11108095 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2AALDH1A1GAA | |
| SCHEMBL27916543 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1830964-B | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof | SHANGHAI INST OF MEDICINES CHINESE ACADEMY OF SCIENCES | 2011-06-15 | — | — | CN | claimed |
| CN-1830964-A | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof | SHANGHAI INST OF MEDICINES CHI (CN) | 2006-09-13 | — | — | CN | claimed |
| CN-104968200-A | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | WELLSTAT THERAPEUTICS CORP | 2015-10-07 | — | — | CN | disclosed |
| EP-2755982-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039878-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2545060-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2516430-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2503881-A1 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2012-10-03 | — | — | EP | disclosed |
| CN-101410114-B | A3 adenosine receptor allosteric modulators | US GOV HEALTH & HUMAN SERV (US) | 2012-07-04 | — | — | CN | disclosed |
| WO-2011112429-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011087740-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| CN-101410114-A | A3 adenosine receptor allosteric modulators | US GOV HEALTH & HUMAN SERV (US) | 2009-04-15 | — | — | CN | disclosed |
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-03-05 | — | — | US | disclosed |
| CN-1830964-A | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof | SHANGHAI INST OF MEDICINES CHI (CN) | 2006-09-13 | — | — | CN | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0681570-A1 | PROCESS FOR PREPARING QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994017043-A1 | PROCESS FOR PREPARING QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-08-04 | — | — | WO | disclosed |
| EP-0098751-A2 | Quinolinyloxy(amino)phenols and alkoxyphenyloxy(amino)quinolines | ICI AUSTRALIA LIMITED (AU) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | IL2, EIF2AK2, IFNG | RAB9A 3123/4885MEN1 4334/4885KMT2A 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.